Key result
Pioglitazone partially prevented the Angiotensin II-induced reduction in transient outward potassium current density in atrial myocytes (4.8 vs 3.6 pA/pF).
Why the study?
Does pioglitazone prevent Angiotensin II-induced potassium channel remodeling in atrial myocytes?
Does pioglitazone prevent Angiotensin II-induced potassium channel remodeling in atrial myocytes?
Absolute Event Rate: 4.8% vs 3.6%
p-value: p=<0.05
Pioglitazone attenuates Angiotensin II-induced potassium channel remodeling in atrial myocytes, suggesting a potential upstream therapeutic mechanism for preventing atrial fibrillation.
May support pioglitazone for atrial remodeling research; leaves open translation to AF prevention in humans.
BACKGROUND: It has been demonstrated that atrial electrical remodeling contributes toward atrial fibrillation (AF) maintenance, and that angiotensin II (AngII) is involved in the pathogenesis of atrial electrical remodeling. Peroxisome proliferator activated receptor-γ (PPAR-γ) agonists have been shown to inhibit atrial electrical remodeling, but the underlying mechanisms are poorly understood. In the present study we investigated the regulating effects of PPAR-g agonist on AngII-induced potassium channel remodeling in atrial myocytes. MATERIAL/METHODS: Whole-cell patch-clamp technique was used to record transient outward potassium current (Ito), ultra-rapid delayed rectifier potassium (Ikur), and inward rectifier potassium current (Ik1). Real-time PCR was used to assess potassium channel subunit mRNA expression. RESULTS: Compared with the control group, AngII reduced Ito and Ikur current density as well as amplified Ik1 current density, which were partially prevented by pioglitazone. Furthermore, pioglitazone alleviated the downregulation of Ito subunit (Kv 4.2) and Ikur subunit (Kv 1.5), as well as the upregulation of Ik1 subunit (Kir 2.1 and Kir 2.2) mRNA expression stimulated by AngII. CONCLUSIONS: These results suggest that pioglitazone exhibits a beneficial effect on AngII-induced potassium channel remodeling. PPAR-γ agonists may be potentially effective up-stream therapies for AF.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2014) studied Atrial electrical remodeling. Pioglitazone vs. Angiotensin II alone was evaluated on Transient outward potassium current (Ito) density at 50 mV (p=<0.05). Pioglitazone partially prevented the Angiotensin II-induced reduction in transient outward potassium current density in atrial myocytes (4.8 vs 3.6 pA/pF).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: